Literature DB >> 32918180

ASO Author Reflections: Return to Isolated Limb Infusion for In-Transit Melanoma.

Michael J Carr1, Hidde M Kroon2,3, Jonathan S Zager4,5.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32918180     DOI: 10.1245/s10434-020-09113-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  4 in total

1.  Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis.

Authors:  John T Miura; Hidde M Kroon; Georgia M Beasley; Dean Mullen; Norma E Farrow; Paul J Mosca; Michael C Lowe; Clara R Farley; Youngchul Kim; Syeda Mahrukh Hussnain Naqvi; Aishwarya Potdar; Hala Daou; James Sun; Jeffrey M Farma; Michael A Henderson; David Speakman; Jonathan Serpell; Keith A Delman; B Mark Smithers; Brendon J Coventry; Douglas S Tyler; John F Thompson; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2019-03-25       Impact factor: 5.344

2.  Outcomes following isolated limb infusion for melanoma. A 14-year experience.

Authors:  Hidde M Kroon; Marc Moncrieff; Peter C A Kam; John F Thompson
Journal:  Ann Surg Oncol       Date:  2008-05-29       Impact factor: 5.344

3.  Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma.

Authors:  Diego J Muilenburg; Georgia M Beasley; Zachary J Thompson; Ji-Hyun Lee; Douglas S Tyler; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2014-09-06       Impact factor: 5.344

4.  Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions.

Authors:  Cristina O'Donoghue; Matthew C Perez; John E Mullinax; Danielle Hardman; Sean Sileno; Syeda Mahrukh Hussnain Naqvi; Youngchul Kim; Ricardo J Gonzalez; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2017-10-10       Impact factor: 5.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.